The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis sues Cipla for ignoring its COPD drug patents

Novartis has lashed out at India's Cipla in court for rolling out a deeply discounted generic of its COPD drug Onbrez without waiting for the courts to rule whether its patents are valid. It has sued Cipla for infringing its patents on Onbrez, known as Arcapta in the U.S.

Fresh off Afinitor failure, Novartis turns tide with Signifor LAR approval

It's been a good news, bad news week for Novartis and its oncology business. Monday, the Swiss drugmaker won FDA approval for a long-acting version of Signifor, to treat acromegaly, a rare endocrine disorder. But Friday, Novartis announced that Afinitor fell short in a HER2-positive breast cancer trial, dashing hopes for what could have been a lucrative new indication.

Novartis wins an FDA nod for a long-acting spin on its rare disease drug

The FDA signed off on a once-a-month version of Novartis' Signifor designed to treat acromegaly, a rare growth hormone disorder that can lead to disfigurement and death.

Novartis psoriasis prospect tops J&J's fast-growing Stelara in PhIII

J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested the drug in a head-to-head trial.

Novartis' bid to widen Afinitor's breast cancer reach falls short in PhIII

Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod for HER2-positive advanced breast cancer. But no such luck: On Friday, the drugmaker announced its treatment had come up short in a Phase III trial.

Novartis' psoriasis drug tops J&J's Stelara as it speeds toward approval

Novartis' new anti-inflammatory treatment cleared up psoriasis better than Johnson & Johnson's Stelara in a Phase III trial, a second head-to-head victory for the injectable drug as it nears U.S. and European approvals.

More Novartis jobs cut in New York as plant suffers drawn-out drawdown

Novartis continues the protracted drawdown at its Diovan plant in New York, telling the state nearly two dozen more jobs will be whacked starting at the end of March.

Prepping for big heart drug launch, Novartis cuts 200 primary care sales staffers

Even a megablockbuster launch isn't enough to save Novartis sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly anticipated heart failure drug.

Novartis lays off 200 primary care reps as it preps for megablockbuster LCZ696 rollout

Even a megablockbuster launch isn't enough to save Novartis sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly anticipated heart failure drug.

Novartis adds to CAR-T's luster with more excellent cancer data

A new cancer treatment from Novartis and its partners at the University of Pennsylvania came through in another round of early studies, posting stellar results and burnishing the promise of therapies that train the immune system to bear down on tumor cells.